A state public health department reviews a retrospective cohort study evaluating a newly a… — USMLE Step 3

A state public health department reviews a retrospective cohort study evaluating a newly approved inhaled pulmonary vasodilator for the prevention of recurrent exacerbations in patients with severe chronic obstructive pulmonary disease (COPD). The primary analysis reports a crude relative risk (RR) of $1.62$ (95% CI: $1.35-1.94$ ) for recurrent exacerbations in patients using the new vasodilator compared to those on standard therapy. Concerned that concurrent active smoking might influence the outcomes, researchers perform a stratified analysis based on smoking status. In the stratum of active smokers, the RR is $2.85$ (95% CI: $2.10-3.88$ ). In the stratum of non-smokers, the RR is $1.05$ (95% CI: $0.88-1.25$ ). Based on these findings, which of the following best describes the role of active smoking in this study?

It acts as an effect modifier, indicating that the magnitude of the drug's effect differs depending on smoking status.Answer
B
It acts as a confounding variable, indicating that smoking distorts the true overall association between the drug and exacerbations.
C
It represents a Hawthorne effect, suggesting that participants altered their smoking habits due to study observation.
D
It introduces selection bias, indicating that smokers and non-smokers were unequally distributed between treatment groups.
E
It invalidates the calculated relative risks, requiring the use of an independent t-test for categorical data comparison.

Answer

It acts as an effect modifier, indicating that the magnitude of the drug's effect differs depending on smoking status.

The scenario describes a classic presentation of effect modification. Effect modification occurs when a third variable (in this case, active smoking) changes the magnitude of the association between the exposure (pulmonary vasodilator) and the outcome (COPD exacerbations). This is identified statistically through stratified analysis: if the stratum-specific relative risks are significantly different from one another (

2.85

vs.

1.05

), the third variable is an effect modifier. In such cases, it is inappropriate to report the crude relative risk alone; instead, the results should be reported separately for each stratum.

Step-by-Step Solution

Identify the study design and the reported statistical measures.

The study is a retrospective cohort study reporting a crude relative risk of

1.62

Establishing the baseline measurement of association before stratification is necessary to compare results.

Examine the results of the stratified analysis based on the third variable (active smoking).

The relative risk is

2.85

for active smokers and

1.05

for non-smokers.

Stratification is the primary method used to distinguish between confounding and effect modification in epidemiology.

Compare the stratum-specific relative risks to each other.

The stratum-specific relative risks (

2.85

and

1.05

) are substantially different from each other, and their confidence intervals do not overlap.

When stratum-specific estimates differ significantly from one another, the third variable is modifying the biological or clinical effect of the exposure, confirming effect modification.

Key Concept

Effect modification occurs when the magnitude or direction of an association between an exposure and an outcome varies according to the level of a third variable. It is identified when stratum-specific measures of association differ significantly from each other.

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic